En Israël, le NanoKnife coûte généralement de $18,500 à $31,500 selon la complexité tumorale et l'établissement choisi. Les tarifs dépendent de l'organe traité, du nombre d'électrodes et de la durée d'hospitalisation nécessaire. Les patients économisent environ 23% par rapport à la France, où l'acte coûte en moyenne $24,000. Les forfaits hospitaliers israéliens incluent souvent l'ablation, l'anesthésie, les bilans sanguins préopératoires et l'imagerie spécialisée comme le PET-scan PSMA.
Avis d'expert Bookimed : Opter pour un centre multidisciplinaire comme le Sourasky Medical Center (Ichilov) apporte une réelle valeur aux patients en oncologie. Bien que les forfaits NanoKnife y débutent autour de 27 550 €, ils offrent 90 % de taux de succès oncologique. Ichilov est accrédité par la JCI et figure au classement Newsweek des meilleurs hôpitaux mondiaux. Avec 34 000 opérations par an, l'établissement garantit une expertise chirurgicale approfondie. Pour les cas complexes, les spécialistes comme le professeur Jack Baniel offrent un accès à la recherche urologique mondiale. Les structures privées comme Assuta, facturées environ 38 700 €, privilégient des délais réduits et un service personnalisé en milieu accrédité JCI.
Pourquoi envisager Israël pour un traitement par nanoknife ?
Accédez à des solutions avancées de NanoKnife dans des cliniques de confiance .
| Israël | Turquie | Espagne | |
| NanoCouteau | de $18,500 | de $9,500 | de $12,000 |
Dr. Arnon Nagler is a hematologist at Sheba Medical Center in Israel. He is a professor at Tel Aviv University and a renowned transplant expert. Dr. Nagler founded Israel’s first public cord blood bank. He also performed the first cord blood transplantations in the country. He completed postdoctoral training at Stanford University and is board-certified in hematology.
Dr. Barak Rosenzweig directs the Urological Oncology Service at Sheba Medical Center in Israel. He is a surgeon who has been listed among Israel’s Best Doctors by Forbes. Dr. Rosenzweig specializes in treating tumors of the prostate, kidney, bladder, and testis. He focuses on robotic and minimally invasive cancer surgery to preserve organ function.
Dr. Almog Ben Yaacov is a senior surgical oncologist at Sheba Medical Center. He has performed over 200 HIPEC procedures for complex abdominal cancers. He focuses on treating gastric cancer, sarcoma, and colorectal malignancies. Dr. Ben Yaacov holds board certifications in both General Surgery and Surgical Oncology.
Expert de premier plan en technologie NanoKnife, spécialisé dans les tumeurs malignes thoraciques et le profilage génomique innovant au centre médical Sourasky.
NanoKnife is a safe, minimally invasive procedure for destroying tumors without heat or cold. It utilizes irreversible electroporation (IRE) to protect vital blood vessels, nerves, and ducts. Facilities such as Sourasky Medical Center and Assuta Medical Center maintain high safety standards through JCI-accredited protocols in Tel Aviv.
Bookimed Expert Insight: Safety outcomes in Israel are driven by high institutional volume and surgeon specialization. Sourasky Medical Center treats 40,000 oncology patients annually. This massive scale ensures doctors manage complex cases frequently. It also explains why Israel is a top 5 global destination for this specific procedure.
Patient Consensus: Many choose this for its low impact on quality of life compared to surgery. However, patients emphasize that post-procedure monitoring with MRIs is essential to manage long-term success.
NanoKnife for prostate cancer achieves a 97% success rate in eradicating primary tumors through Irreversible Electroporation. This non-thermal focal therapy preserves quality of life, maintaining urinary continence in 95–99% of patients while protecting erectile function for 70–85% of men treated in Israel.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center maintain high success through strict selection. While short-term eradication reaches 97%, effectiveness drops for patients outside low-to-intermediate risk categories. Specialist training at institutions like Memorial Sloan Kettering ensures surgeons maximize nerve-sparing benefits during these procedures.
Patient Consensus: Patients value the ability to repeat the procedure or switch to surgery if needed. Practical concerns focus on the necessity of self-funding, as insurance coverage remains limited for this focal therapy.
NanoKnife technology in Israel is a minimally invasive treatment for localized prostate cancer and unresectable soft tissue tumors. It uses irreversible electroporation (IRE) to destroy cancer cells with electrical pulses. This non-thermal approach protects vital structures like nerves and blood vessels near the prostate or pancreas.
Bookimed Expert Insight: While NanoKnife is famous for prostate care, major Israeli oncology centers use it as a strategic alternative for tumors near critical arteries. Our data shows specialized surgeons often combine this with advanced genetic testing to confirm the patient is a candidate for focal therapy over radical surgery.
Patient Consensus: Patients value how this focal therapy preserves their quality of life compared to traditional surgery. Many choose Israeli clinics specifically because surgeons here are early adopters of this technology for complex, soft-tissue cases.
NanoKnife uses irreversible electroporation (IRE) to destroy tumors with high-voltage electrical pulses. Unlike traditional ablation, this non-thermal technology creates permanent microscopic holes in cancer cell membranes. This process triggers natural cell death while preserving vital structures like blood vessels, nerves, and bile ducts.
Bookimed Expert Insight: Israeli oncology centers like Sourasky or Assuta integrate NanoKnife into focal therapy protocols for inoperable cases. While many systems focus on heat, Israel’s focus on IRE allows surgeons to treat tumors nearly touching major arteries. This technical edge is why specialized surgeons like Dr. Almog Ben Yaacov undergo advanced training at global centers like Memorial Sloan Kettering.
Patient Consensus: Patients value how this method spares critical anatomy, though many emphasize that success depends entirely on precise probe placement. Most recommend verifying if your specific tumor size and location allow for complete electrode coverage before proceeding.
NanoKnife recovery in Israel is remarkably fast due to its non-thermal, minimally invasive approach. Patients treating pancreatic cancer typically recover within 1 week, while prostate cancer patients return to normal activities in 9 to 14 days at JCI-accredited facilities like Assuta or Sourasky.
Bookimed Expert Insight: While recovery appears immediate, prostate patients often face a second phase of healing. Data shows that even though you are mobile in 9 days, urinary urgency often persists for 4 weeks. Israel clinics like Sheba Medical Center use specialists trained at King’s College to manage these specific post-op symptoms.
Patient Consensus: Patients value the swift return to mobility but emphasize the importance of the 5-day catheter period. They advise not rushing back to exercise until the 2-week mark to prevent internal bleeding.
Patients can receive NanoKnife treatment at leading Israeli hospitals including Sourasky Medical Center, Assuta Medical Center, and Sheba Medical Center. These JCI-accredited facilities provide irreversible electroporation (IRE) for soft tissue ablation, specializing in targeted therapy for prostate, pancreatic, and liver cancers.
Bookimed Expert Insight: Israeli oncology centers like Sourasky serve 40,000 cancer patients annually, creating a high-volume environment for localized therapies. While Assuta is the largest private surgical complex, major state centers like Sheba often house doctors with specific specialized training from King’s College or MD Anderson.
Patient Consensus: Patients should note that NanoKnife is often considered an experimental elective procedure. Eligibility typically depends on specific MRI imaging results, PSA levels, and tumor location within soft tissues.